Checkpoint inhibitors, autologous whole tumor cancer vaccine, dendritic cell vaccine, supportive oligonucleotide (SOT)
Cancer immunotherapy works through the immune system to control cancer, therefore it directly targets the immune cell rather than the tumor cell. Cancer immunotherapy is aimed at restoring or enhancing the capability of immune cells to recognize and destroy cancer cells.
Cancer immunotherapy is a personalized medicine because each patient has his or her own unique immune response to cancer. The uniqueness of immune responses to cancer is not only determined by the diversity and specificity of her immune system but also by the recognition of tumor antigens within each patient. T-lymphocyte cell function is of critical importance. The optimal dose and the timing of immunotherapy is essential. Obtaining needed biomarkers to identify and evaluate the response to immunotherapy is vital.
The immune system is a network of cells, signals, and organs that help protect against dangerous pathogens and cancer. All types of white blood cells have roles in the immune system. The immune cells that respond in cancer early are part of the innate immune response and include neutrophils, eosinophils, basophils, dendritic cells, natural killer cells, and macrophages derived from monocytes. Immune felt that response later to specifically targeted antigens presented cells, also called dendritic cells and macrophages. They are involved in the adaptive immune response and include helper T cells and cytotoxic T cells.
The immune system plays a dual role in cancer and has both antitumor and pro-tumor effects. On the one hand, our immune cells can recognize and eliminate tumor cells, including the killing of virus-infected cells. On the other hand, the immune system may exert the pressure that shapes the antigens displayed by the tumor cells leading to invasion of the immune system and cancer promotion. One of the hallmarks of cancer is the escape from the immune response. Overall, the role of the immune system is influenced by the tumor, and the tumor is affected by the immune system.
Immunotherapy for Cancer
Tumor suppression and tumor promotion play a role in successful therapy. The cancer immunity cycle consists of the initial release of cancer cell antigens during tumor cell death and the presentation of these antigens to our T-lymphocyte cells in our lymph nodes. They then are transported to our bloodstream into the tumors. It is this infiltration of T lymphocyte cells into the tumors that recognize cancer cells and ultimately caused tumor cell death.
Research now shows that it is the infiltration of the T-lymphocyte that is one of the critical factors in the death of your tumor. It is crucial to raise these during treatments. It is also vital to decrease the number of myeloid suppressor cells and T regulatory cells. This is accomplished throughout the treatment protocol.
Progress in understanding fundamental aspects of cellular immunology and tumor-host immune interactions has led to the development of immune-based therapies. Studies of immunotherapy have focused on enhancing antitumor immune responses of T cells that recognize cancer antigens. Antibodies that recognize growth factors on the surface of the tumors can contribute to tumor regression, primarily by interfering with growth signals rather than the direct destruction of tumor cells. This is the use of monoclonal antibodies in cancer treatment.
These include direct immunization of patients with various autologous whole cancer vaccines, dendritic cell vaccines, interleukin-2, checkpoint inhibitors, and supportive oligonucleotide technique (SOT). Several cancer patients require more than a single agent to respond. Complete remission all may require multiple drugs acting on different targets. Many immunotherapy regimens have been tried in combination with cancer patients, and some have yielded impressive results.
Due to the progress over the last ten years, we now know that the antitumor responses seen with these immune-based modalities appear to be durable and, in some patients, potentially curative. By using various forms of immunotherapy synergistically, we can cause tumor regression.
Low-dose targeted chemotherapy, along with targeted non-toxic natural substances, are used. Immunotherapy with checkpoint inhibitors, whole tumor cancer cell vaccines, dendritic cell vaccines, and supportive oligonucleotide (SOT) are combined in a synergistic treatment program unique to each patient. The reason for further tests is that cancer cells do their best to hide from the detection of the immune system. Tumor systems also can take advantage of the breaks in the immune system.
If you would like more information concerning immunotherapy, please call us at 480-860-2030.